Genmab Announces New Phase III Combination Study of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

Company Announcement

  • Additional Phase III study of daratumumab in front line multiple myeloma
  • Daratumumab in combination with  bortezomib, thalidomide and dexamethasone (VTD)
  • Study expected to start in Q2 2015

Copenhagen, Denmark; November 10, 2014 – Genmab A/S (OMX: GEN) announced today that the French Intergroup of Myeloma (IFM)  in collaboration with  Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON)  and Janssen Biotech, Inc. (Janssen) plans to start an additional Phase III study of daratumumab in frontline multiple myeloma. The study (MMY3006) will compare daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTD) to bortezomib, thalidomide and dexamethasone alone as front line treatment for patients who are candidates for stem cell transplantation (SCT). The study is planned to start in Q2 2015. The first Phase III study in front line multiple myeloma was announced in July and is expected to start towards the end of this year, with the two other Phase III front line studies to start next year. In total today’s news is the fifth daratumumab Phase III study to be announced.

“The daratumumab development plan is progressing at a very fast pace and we are very pleased to announce yet another Phase III study. The expansive development program covers different stages of multiple myeloma, and this will be the third Phase III study to enroll patients newly diagnosed with the disease,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About the MMY3006 study
This Phase III study is a randomized, open-label, multicenter study and will include approximately 1,000 newly diagnosed subjects with previously untreated symptomatic multiple myeloma who are eligible for high dose chemotherapy and stem cell transplant. In the first part of the study, patients will be randomized to receive induction and consolidation treatment with daratumumab combined with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone (a corticosteroid) or bortezomib, thalidomide and dexamethasone alone. The primary endpoint of this part of the study is the number of patients that achieve a stringent Complete Response (sCR). In the second part of the study, patients that achieved a response will undergo a second randomization to either receive daratumumab maintenance treatment for a maximum of 2 years versus no further treatment (observation). The primary endpoint of this part of the study is progression free survival (PFS).

About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.  Daratumumab has been granted Breakthrough Therapy Designation from the US FDA  for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies. 

Company Announcement no. 52
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 93

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 100

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 181

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 27

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 204

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 26

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 9

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 267

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 74

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading

Top 5 Most Recently Viewed Articles

Ping An Healthcare Delivers Impressive Growth in Interim Results

Updated Category News Views 186

Impressive Interim Results from Ping An Healthcare Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) has announced robust interim results for the six-month period ending June 30, showing significant progress following its return to profitability. Throughout this period, the Company has demonstrated strong revenue growth and a notable...

Continue Reading
Market Insights: Trends in Precious Metals and Sector Performance

Updated Category News Views 201

Understanding Market Dynamics and Precious Metals The current landscape of Wall Street might appear quiet at first glance, especially during the lull between holidays. However, beneath this surface lies a surge of activity, particularly in the realm of precious metals. Investors are keenly observing the uptick in volatility, specifically concerning silver and other key...

Continue Reading
Discover the Most Popular Pet Breeds of 2025: Insights and Trends

Updated Category News Views 409

Understanding the 2025 Top Pet Breeds The bond between pets and their owners often mirrors our own personalities and values. Recent insights reveal that 8 out of 10 pet parents believe a dog breed reflects a person's character. Across different breeds, qualities such as friendliness, sociability, and playfulness top the charts when pet parents make their choices. The...

Continue Reading
Amicus Therapeutics Engages Investors at Key Conferences Soon

Updated Category News Views 129

Amicus Therapeutics to Present at Upcoming Investor Conferences Amicus Therapeutics (Nasdaq: FOLD), a dedicated player in the biotechnology landscape, has announced its forthcoming participation in significant investor conferences this September, showcasing its unwavering commitment to fostering investor relations. Details of the Upcoming Presentations The company has...

Continue Reading
Understanding RPM Intl's P/E Ratio in Market Context

Updated Category News Views 206

Understanding RPM Intl's Stock Performance Currently, RPM Intl Inc. (NYSE: RPM) is experiencing a share price of $123.50, reflecting a modest increase of 0.36%. This uptick is notable amidst a turbulent month, where the stock has decreased by 11.21%. However, when we look back over the past year, we see a positive trend, with the stock appreciating by 16.26%. Investors...

Continue Reading